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 22 
Purpose of review:  23 
As more people live longer with cancer, the number of patients with cancer and multiple 24 
other chronic conditions (multi-morbidity) has increased.  The presence of multi-morbidity 25 
impacts on all stages of cancer care, from prevention and early detection through to end of 26 
life care, but research into cancer and multi-morbidity is in its infancy.  This review explores 27 
the impact of multi-morbidity on adults living with (and beyond) cancer, with particular 28 
attention paid to the role of primary care in supporting patients in this situation. 29 
 30 
Recent findings:  31 
Patterns of multi-morbidity vary depending on cancer type and stage, as well as population 32 
characteristics and available data (e.g. number of conditions assessed).  Cancer survivors 33 
are at increased risk of developing other chronic conditions, due to a combination of shared 34 
risk factors (e.g. smoking and obesity), effects of cancer treatments, and psychosocial 35 
effects.  36 
 37 
Summary:  38 
Primary care has a central role to play in supporting multi-morbid adults living with cancer, 39 
providing holistic care of physical and mental well-being, while taking treatment burden and 40 
social circumstances into account.  New models of person-centred and personalised cancer 41 
care include holistic needs assessments, care planning, treatment summaries, and cancer 42 
care reviews, and depend on improved communication between oncologists and primary 43 
care colleagues. 44 
 45 
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Introduction  47 
Multi-morbidity is usually defined as the co-occurrence of two or more long-term conditions 48 
in any individual.  The term promotes a person-centred approach, in contrast to the more 49 
disease-centred term “co-morbidity” where a patient is identified by their index condition and 50 
any additional health problems are considered co-morbidities.  It is now widely recognised 51 
that most people with any long-term condition are more likely to have multi-morbidity than to 52 
have a single condition – multi-morbidity is the norm in chronic illness (1).  Furthermore, the 53 
onset of multi-morbidity occurs roughly 10 to 15 years earlier in patients living in the most 54 
deprived areas compared to the most affluent (1).  These observations have significant 55 
implications for health care, research and medical education, as outlined in the landmark 56 
2012 Lancet paper on the epidemiology of multi-morbidity (1).  Multi-morbidity matters 57 
because it is associated with adverse health outcomes, including higher mortality, poor 58 
quality of life, lower functional status, and higher rates of hospital admissions (2-4).  Yet the 59 
optimal healthcare response to patients with multi-morbidity is unclear, and the majority of 60 
existing evidence is in populations of older people with little research on the larger number of 61 
people under 65 years of age with multi-morbidity (1, 5, 6). 62 
 63 
In relation to cancer, the presence of multi-morbidity impacts on all stages of care, from 64 
prevention and early detection through to end of life care (7-10).  Cancer prevention is 65 
complicated by multi-morbidity because many of the modifiable risk factors associated with 66 
the prevention of cancer (e.g. smoking, alcohol, poor diet, physical inactivity) are also linked 67 
to long-term conditions such as diabetes, chronic obstructive pulmonary disease (COPD), 68 
cardiovascular disease (CVD), arthritis, and mental health conditions, the symptoms of 69 
which can make enacting behaviour change more challenging.  Furthermore, many people 70 
have multiple unhealthy behaviours, with particular clustering in areas of socio-economic 71 
deprivation (11), adding further complexity (12). 72 
  73 
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Detecting cancer early can also be affected by multi-morbidity, with some patients having 74 
their cancer diagnosed earlier due to frequent contacts with health services, and others 75 
being diagnosed later if they attribute symptoms to comorbid conditions, as in the case of 76 
COPD and lung cancer (13). 77 
 78 
The focus of this review, however, will be on the impact of multi-morbidity on adults living 79 
with (and beyond) cancer, with particular attention paid to the role of primary care in 80 
supporting patients in this situation.  There is a complementary review in this issue which 81 
focusses on multi-morbidity in older adults with cancer (REF Corbett and Bridges paper) 82 
 83 
We searched PubMed, EMBASE and Google Scholar using search terms in three broad 84 
categories relating to multi-morbidity, cancer, and primary care.  We also used citation 85 
searching and articles from our personal collections to allow a thorough review of the 86 
subject.  The majority of research articles we reviewed were published within the last 18 87 
months and all were written in English.  88 
 89 
Common patterns of multi-morbidity in adults living with cancer  90 
Cancer incidence increases with age, as does the incidence of multi-morbidity.  With ageing 91 
populations in most high-income countries, people are now more likely to develop cancer 92 
while already having other chronic conditions.  Furthermore, with recent advances in cancer 93 
diagnosis and treatment, people are also living longer with cancer, and therefore more likely 94 
to develop other chronic diseases during their lifetime. 95 
 96 
Figure 1 provides an illustration of the extent of multi-morbidity for people with any cancer, in 97 
a nationally representative sample of the Scottish population (1).  Particularly common co-98 
morbidities were painful conditions, depression, anxiety, coronary heart disease, diabetes, 99 
and COPD, and all of these were more prevalent in the most deprived decile compared to 100 
the most affluent.   101 
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 102 
[INSERT FIGURE 1. Legend = Selected comorbidities in people with cancer and three other 103 
common, important disorders in the most affluent and most deprived deciles. 104 
COPD=chronic obstructive pulmonary disease. TIA=transient ischaemic attack.] 105 
 106 
More recently, Zemedikun et al analysed UK Biobank Data to establish patterns of multi-107 
morbidity in adults aged 40 to 69 years (14).  19% of study participants had 2 or more 108 
chronic conditions, with hypertension, asthma and cancer being the three most common 109 
conditions (cancer prevalence was 8.3%).  Cancer was associated with nine other conditions 110 
in their cluster analysis, including hypertension, asthma, anxiety, depression, eczema, 111 
irritable bowel syndrome, and migraine.  112 
 113 
Patterns of multi-morbidity vary depending on cancer type and stage, as well as population 114 
characteristics and limitations of data (e.g. number of conditions assessed).  For example, 115 
Williams et al assessed co-morbidities in older adults with different cancers in the US (15)*. 116 
Overall, 92% of participants reported one or more co-morbid condition, with a mean of 2.7 117 
conditions (range 0 to 10).  Approximately half of all patients reported arthritis and 118 
hypertension, but there were important differences in co-morbidities by cancer type. 119 
Circulatory problems, diabetes, heart disease, and depression were also common (affecting 120 
around 20%), in keeping with other studies that have explored co-morbidities associated with 121 
different cancers (16, 17).  122 
 123 
The mechanisms underlying relationships between certain cancers and certain co-124 
morbidities have been explored.  Many cancers share common risk factors (smoking, 125 
obesity, alcohol) with conditions such as hypertension, cardiovascular disease (CVD), 126 
diabetes, and COPD, but there is recent evidence to suggest that certain chronic diseases 127 
themselves (e.g. diabetes and chronic kidney disease) may predispose to cancer (18).  128 
 129 
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Some pre-existing conditions also increase the risk of developing cancer treatment-related 130 
complications.  For instance, patients with cardiovascular disease, diabetes or 131 
hypercholesterolaemia are more likely to develop cardiovascular side effects, especially left 132 
ventricular dysfunction, from anticancer therapy (19)*.  Similarly, patients receiving androgen 133 
deprivation therapy in the treatment of prostate cancer have been shown to be at increased 134 
risk for developing diabetes (20).   135 
 136 
Illness and treatment burden in multi-morbid adults living with cancer 137 
There are several important implications of multi-morbidity for adults living with cancer.  As 138 
noted above, multi-morbidity is associated with lower quality of life and poorer functional 139 
status and this can affect cancer treatment outcomes and therefore treatments offered.  The 140 
concepts of illness and treatment burden may be helpful in guiding discussions and decision-141 
making related to cancer treatment and support. 142 
 143 
Illness burden refers to the “work” involved in living with a chronic illness and includes 144 
physical, emotional, social and existential elements (10).  This burden of illness is closely 145 
related to the number and severity of symptoms (e.g. pain, fatigue, breathlessness) that a 146 
patient is experiencing, but is also influenced by the patient’s capacity to understand and 147 
manage their different conditions and symptoms. 148 
 149 
Treatment burden refers to the “work” that patients (and their families or carers) are asked to 150 
perform to respond to the requirements of their healthcare providers, as well as the impact 151 
that this work has on patient functioning and wellbeing (21).  Research on treatment burden 152 
in patients with multi-morbidity has highlighted issues such as polypharmacy and complex 153 
medication regimes, fragmentation of care across different specialities, and challenges 154 
related to lifestyle changes and self-monitoring (22, 23).  155 
 156 
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Figure 2 shows an adaptation of the cumulative complexity model, a patient-centred 157 
framework that incorporates illness and treatment burdens but also emphasises the 158 
workload-capacity balance (24).  Capacity in this context refers to the abilities, resources, or 159 
readiness to address the demands of illness and treatment.  These resources include 160 
physical and mental functioning, socioeconomic resources, social support, literacy, and 161 
attitudes/beliefs (24).   162 
 163 
[INSERT FIGURE 2. Legend = The cumulative complexity model (adapted from Shippee et 164 
al (24) 165 
 166 
A recent qualitative systematic review and synthesis of evidence on the experience of 167 
cancer and co-morbid illness suggests there is still considerable room for improvement in 168 
addressing the workload-capacity balance to better support multi-morbid adults living with 169 
cancer (25)**.  The authors identified five key themes from the 31 included studies: 1) the 170 
interaction and impact of cancer and co-morbidity (which affected not only quality of life and 171 
recovery, but also treatment decisions); 2) the complex symptom burden and experience 172 
(which was variable and mediated for some by cancer stage and severity but also led to 173 
blurring of symptoms and attribution difficulties for others); 3) illness expectations and 174 
identity when facing complex illness (which was influenced by past experience of illness as 175 
well as notions of ageing and expectations of ailing health and function); 4) managing 176 
medications and self-management (which emphasised the need for shared care and 177 
resources to support self-management); and 5) the role of primary and secondary care in 178 
meeting survivorship needs (which highlighted the at times fragmented experience of care). 179 
 180 
Some of these findings reflect wider trends in cancer treatment, such as the shift towards 181 
shorter inpatient stays and a greater emphasis on management (and self-management) 182 
closer to home, with patients and carers encouraged to be more responsible for their care. 183 
Furthermore, the increasing use of oral chemotherapy has presented new challenges for 184 
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patients and healthcare providers (26).  Oral regimens can be complex, comprised of 185 
multiple medications with varying dosages and instructions, and requiring patients and 186 
primary care practitioners to recognise side effects and potential interactions. 187 
 188 
Common side effects of oral chemotherapy treatments include nausea, fatigue, diarrhoea, 189 
oral mucositis, sleep disturbance, skin conditions (e.g. rashes, blisters, dry skin), and 190 
neuropathy.  Managing these at home may require dose modifications, interruptions, 191 
discontinuing treatment, or admission to hospital, all of which require communication 192 
between patients and their healthcare providers, ideally in primary and secondary care. 193 
 194 
Patients with multi-morbidity are more likely to be prescribed multiple medications (known as 195 
polypharmacy) and primary care practitioners are well placed to assess polypharmacy and 196 
identify potentially inappropriate medications (PIMs), with a high risk-to-benefit ratio.  A 197 
recent study of older patients with breast and colorectal cancer found that roughly 30% were 198 
on PIMs (27).  A similar study found even higher rates of PIMs (over 65% for patients with 199 
colorectal cancer) and significant associations with increased healthcare utilisation and 200 
higher costs (28). 201 
 202 
The role of primary care in supporting multi-morbid adults living with cancer 203 
The role of primary care in supporting patients living with and beyond cancer was well 204 
summarised in a 2018 review in this journal, which emphasised the strengths of primary care 205 
as contact, comprehensiveness, continuity and coordination (29).  These four pillars of 206 
primary care are particularly important in the context of adults with multi-morbidity, who 207 
account for over half of all GP consultations and nearly 80% of prescriptions (30). 208 
 209 
Despite these apparent strengths, it is well recognised that GP input during cancer treatment 210 
and survivorship phases is highly variable, both within and between countries (31).  Rubin et 211 
al outlined the following areas as being particularly important for primary care practitioners 212 
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(PCPs) to optimise care: long-term and late effects of cancer treatment; psychosocial 213 
effects; detection of recurrence; prevention; and models to deliver survivorship care (31).  All 214 
of these aspects of care are potentially more complex in the presence of multi-morbidity.  215 
 216 
Knowledge of the long-term and late effects of cancer treatment was recognised as one of 217 
several learning gap for PCPs in relation to cancer survivorship care (32).  While primary 218 
care practitioners (GPs and practice nurses) may be well used to supporting adults with 219 
multi-morbidity, providing holistic care of physical and mental well-being, and taking social 220 
circumstances into account, it is clear that people living with cancer have unmet physical, 221 
psychosocial and spiritual needs (33, 34). 222 
 223 
Psychosocial needs of multi-morbid patients with cancer were explored in a qualitative study 224 
from Australia which showed how multi-morbid illness representations can influence self-225 
management (35)*.  Most of the study participants – who had cancer and anxiety/depression 226 
– viewed the conditions as intertwined.  A range of cancer-related consequences were 227 
perceived as causing anxiety/depression, including visible scars from treatment, physical 228 
disabilities, hair loss, inability to work, fertility difficulties, and loss of independence (35)*. 229 
 230 
The fear of cancer recurrence (FCR) was common and manageable for most, but for some 231 
people it could become debilitating, resulting in unhelpful coping behaviours (e.g. becoming 232 
“engrossed in Dr Google”) and worsening their anxiety/depression.  This is in keeping with 233 
the growing body of research on FCR (36, 37), suggesting that screening for and monitoring 234 
of psychosocial effects (such as FCR) should be a routine part of cancer care reviews in 235 
primary care. 236 
 237 
The role of primary care in the preventive care of cancer survivors is also gaining increasing 238 
attention (38).  Preventive care relates to the prevention of morbidity and premature mortality 239 
in individuals and is traditionally considered in terms of primary, secondary and tertiary 240 
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prevention.  For cancer survivors, the prevention of further cancers and cardiovascular 241 
disease are priorities.  One recent study found that approximately 25% of older adults (≥65 242 
years) and 11% of younger adults had a history of prior cancer, with most of these new 243 
cancers diagnosed in different anatomic locations (39)*.  Cancer survivors are at increased 244 
risk of CVD, due to a combination of shared risk factors (e.g. smoking and obesity), 245 
cardiotoxic effects of cancer treatments, and sub-optimal CVD prevention (40).  Primary care 246 
therefore has a key role in supporting health behaviour change related to smoking, alcohol, 247 
diet and physical activity, as well as in optimising adherence to statins when indicated. 248 
 249 
With regard to models of care for supporting multi-morbid adults living with cancer, there is 250 
no consensus on the optimal approach, although all models include improved 251 
communication between oncologists and primary care colleagues (41).  Traditional follow-up 252 
care based on routine appointments for years following treatment is now considered to be 253 
neither sustainable nor effective (42).  In the UK, recommendations for person-centred and 254 
personalised (stratified) care for people affected by cancer include holistic needs 255 
assessments, care planning, treatment summaries (including information about risk of 256 
recurrence and known risks from treatments), access to educational ‘health and wellbeing’ 257 
events, and cancer care reviews (43).   258 
 259 
Implications for future research 260 
Supporting people with multiple chronic illnesses (multi-morbidity) to live well with (and 261 
beyond) cancer requires robust evidence of what works, for whom, and in what 262 
circumstances.  At present, the majority of clinical practice cancer guidelines are derived 263 
from clinical trials that exclude medically complex older adults (and those from poorer socio-264 
economic backgrounds (44)).  This is often for rational scientific reasons – for instance, to 265 
avoid interactions of other prescribed medications with the trial drug – but there are growing 266 
calls for cancer trials to be more pragmatic and less exclusive (45, 46). 267 
 268 
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Research in patients with cancer and multi-morbidity poses several methodological 269 
challenges due to heterogeneous study populations, difficulties with recruitment and a 270 
variety of relevant outcome measures (47).  Patient-reported outcome measures will 271 
increasingly inform the development of health services and other forms of support to limit the 272 
disruption to everyday lives of patients (and their carers) who are living with cancer (42, 48). 273 
 274 
Conclusion 275 
As more people live longer with cancer, the number of patients with cancer and multiple 276 
other chronic conditions will also increase.  Primary care has a central role to play in 277 
supporting multi-morbid adults living with cancer, identifying physical, psychosocial and 278 
spiritual needs, and signposting to financial support if necessary. 279 
 280 
It has been ten years since May and colleagues called for healthcare to be “minimally 281 
disruptive” to patients with chronic illness, tailoring treatment regimens to the realities of 282 
patients’ daily lives (23). Healthcare practitioners must take into account both workload 283 
demands and patient capacity when supporting patients living with cancer, asking questions 284 
such as: “Can you really do what we are asking you to do?” and “Do you think what we are 285 
asking you to do is the right thing for you?”(49) 286 
 287 
  288 
12 
 
Key points 289 
• As people live longer with cancer, multi-morbidity is becoming the norm, with 290 
implications for health care, research and medical education. 291 
• There is a strong social gradient in multi-morbidity, with onset 10-15 years earlier in 292 
more deprived areas. 293 
• Health services need to consider illness and treatment burden, as well as patient’s 294 
existing capacity and resources, when discussing cancer treatments. 295 
• New models of person-centred and personalised cancer care depend on improved 296 
communication between oncologists and primary care colleagues. 297 
 298 
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